Ipilimumab/nivolumabMyasthenia gravis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1917卷 / 1期

关键词：

D O I：

10.1007/s40278-022-20196-y

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：325 / 325

相关论文

共 50 条

[31] NivolumabMyasthenia gravis, sinus bradycardia and complete atrioventricular block: Case report: case report
Reactions Weekly, 2018, 1712 (1) : 399 - 399
[32] NivolumabMyasthenia gravis: 12 case reports
Reactions Weekly, 2017, 1673 (1) : 280 - 280
[33] NivolumabMyasthenia gravis Lambert-Eaton overlap syndrome: case report
Reactions Weekly, 2022, 1888 (1) : 287 - 287
[34] Ipilimumab/nivolumabMyositis and myasthenia gravis: case report
Reactions Weekly, 2022, 1911 (1) : 249 - 249
[35] Ipilimumab/pembrolizumabMyasthenia gravis and myositis: case report
Reactions Weekly, 2018, 1728 (1) : 201 - 201
[36] Ipilimumab/nivolumabMyocarditis and myasthenia gravis: case report
Reactions Weekly, 2023, 1949 (1) : 255 - 255
[37] Ipilimumab/NivolumabMyocarditis and myasthenia gravis: case report
Reactions Weekly, 2025, 2052 (1) : 226 - 226
[38] Ipilimumab/methylprednisolone/nivolumabMyocarditis and myasthenia gravis: case report
Reactions Weekly, 2021, 1864 (1) : 200 - 200
[39] Cemiplimab/nivolumabMyasthenia gravis and ocular myasthenia: 2 case reports
Reactions Weekly, 2022, 1888 (1) : 120 - 120
[40] Ipilimumab/nivolumabImmunotherapy-related myasthenia gravis: case report
Reactions Weekly, 2019, 1750 (1) : 154 - 154

← 1 2 3 4 5 →